Over the last decade, percutaneous intervention for the treatment of aortic stenosis has become commonplace with >300,000 implantations performed worldwide. With this now being an established therapy, focus has shifted to the more intricate challenge of mitral and tricuspid valve disease, where there remains a large population of patients with unmet clinical needs. These complex anatomical structures demand unique approaches to treat a wide range of pathologies involving the valve leaflets, annulus and chordae. A large armamentarium of devices is under evaluation in preclinical animal studies or preliminary clinical trials. Herein, we review the technical characteristics of mitral and tricuspid devices in current clinical application and summarise the available data concerning their use in humans.